Clinical Trials on Gastroenteropancreatic

Total 48 results

Grupo Espanol de Tumores Neuroendocrinos

Active, not recruiting

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Neuroendocrine Tumors | Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine Tumor

Spain
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaborators

Recruiting

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Neuroendocrine Tumors,Gastroenteropancreatic

Taiwan
Amr Mohamed MD
Novatek Pharmaceuticals

Active, not recruiting

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Neuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine Neoplasm

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Advanced Gastroenteropancreatic Neuroendocrine Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

Advanced Gastroenteropancreatic Neuroendocrine Tumor
University Hospital, Basel, Switzerland
Swiss National Science Foundation; Paul Scherrer Institute (PSI)

Recruiting

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3) (Beta plus)

Neuroendocrine Neoplasia's (NENs) | Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Switzerland
University Hospital, Antwerp
Erasmus Medical Center; ZonMw: The Netherlands Organisation for Health Research... and other collaborators

Recruiting

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients (SAUNA)

Gastroenteropancreatic Neuroendocrine Tumor

Netherlands, Belgium
Novartis Pharmaceuticals

Completed

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (COOPERATE-1)

Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System

Germany
H. Lee Moffitt Cancer Center and Research Institute

Completed

Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors

Lung Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine Tumor

United States
University of Iowa
Patient-Centered Outcomes Research Institute; Medical University of South Carolina and other collaborators

Enrolling by invitation

Neuroendocrine Tumors - Patient Reported Outcomes (NET-PRO)

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Lung Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine Tumor

United States
RayzeBio, Inc.

Active, not recruiting

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1)

Neuroendocrine Tumors | Carcinoid Tumor | Gastroenteropancreatic Neuroendocrine Tumor | Carcinoid | GEP-NET | Gastroenteropancreatic Neuroendocrine Tumor Disease | Pancreatic NET

Canada, Spain, United States, Netherlands, Belgium, France, Brazil
Ipsen

Completed

Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs (EXPLAIN)

Gastroenteropancreatic Neuroendocrine Tumors

Finland, Norway, Sweden, Denmark, Latvia, Lithuania, Estonia
Grupo Espanol de Tumores Neuroendocrinos

Recruiting

Nutrition in Gastroenteropancreatic Neuroendocrine Tumor (NUTRIGETNE)

Gastroenteropancreatic Neuroendocrine Tumor

Spain
Stanford University
Novartis Pharmaceuticals

Recruiting

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Gastroenteropancreatic Neuroendocrine Tumor

United States
Advanced Accelerator Applications

Active, not recruiting

Post-Authorization Long-Term Safety Study of LUTATHERA (SALUS)

Neuroendocrine Tumors

United Kingdom, Portugal, Spain, France, United States
Jules Bordet Institute

Completed

177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs (LUMEN)

Gastroenteropancreatic Neuroendocrine Tumors

Belgium
Ipsen

Completed

68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

Gastroenteropancreatic Neuroendocrine Tumors

Switzerland
Peking University

Not yet recruiting

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Neuroendocrine Tumors

China
Wren Laboratories LLC

Active, not recruiting

Surgical Intervention and the NETest (NETest_Sx)

Neuroendocrine Tumor | Gastroenteropancreatic

Italy
Ipsen

Completed

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET (SONNET)

Gastroenteropancreatic Neuroendocrine Tumors

Germany, Austria
IRCCS San Raffaele

Recruiting

68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours

Gastroenteropancreatic Neuroendocrine Tumor

Italy
Jiangsu HengRui Medicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Terminated

A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Gastroenteropancreatic Neuroendocrine Tumor

China
Advanced Accelerator Applications

Active, not recruiting

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Pheochromocytoma | Paraganglioma | Gastroenteropancreatic Neuroendocrine Tumors

United States, Spain, France, Poland, United Kingdom
Advanced Accelerator Applications

Active, not recruiting

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs (REAL-LU)

Gastroenteropancreatic Neuroendocrine Tumor

Italy
Ipsen

Completed

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs (PALACE)

Gastroenteropancreatic Neuroendocrine Tumor

China
Ipsen

Completed

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Gastroenteropancreatic Neuroendocrine Tumor

United States
Ipsen

Completed

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Gastro-Enteropancreatic Neuroendocrine Tumor

United States, Austria, Denmark
Assistance Publique - Hôpitaux de Paris

Recruiting

Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort (OPERANDI-NET)

Radiotherapy | Gastroenteropancreatic Neuroendocrine Tumor

France
Nantes University Hospital

Completed

TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors (68-DOTANOC-GEP)

Patients With Gastroenteropancreatic Neuroendocrine Tumors

France
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

Gastroenteropancreatic Neuroendocrine Tumor G3

China
British Columbia Cancer Agency

Withdrawn

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Neuroendocrine Tumors | Carcinoid Tumor | Gastrinoma | Insulinoma | Vipoma | Gastroenteropancreatic Neuroendocrine Tumor | Pulmonary Carcinoid Tumor

Canada
ITM Solucin GmbH

Recruiting

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE)

Neuroendocrine Tumors

United States, United Kingdom, Australia, Netherlands, France, Italy, Spain, Germany, Sweden, India
Novartis Pharmaceuticals

Active, not recruiting

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Somatostatin Receptor-positive GEP-NET

Korea, Republic of
National Cancer Institute (NCI)

Recruiting

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Neuroendocrine Tumors | Neuroendocrine Neoplasms | Gastroenteropancreatico Tumors

United States
Ipsen

Completed

Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours (STREET)

Gastroenteropancreatic Neuroendocrine Tumours

Sweden
Asan Medical Center

Completed

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Capecitabine | Temozolomide

Korea, Republic of
University Hospital, Bordeaux
Advanced Accelerator Applications

Recruiting

Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases (LUTARTERIAL)

Neuroendocrine Tumor | Liver Metastases | Neuroendocrine Gastroenteropancreatic Tumour

France
Debiopharm International SA

Active, not recruiting

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01)

Acromegaly | GEP-NET

United Kingdom, France, Spain, Italy, Poland, Denmark, Germany, Israel
University Hospital Inselspital, Berne
University Hospital, Basel, Switzerland; University of Lausanne Hospitals; University... and other collaborators

Terminated

Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors (GaIN)

Gastroenteropancreatic Neuroendocrine Tumors

Switzerland
Assistance Publique Hopitaux De Marseille

Completed

[68 Ga]-DOTANOC PET/CT in GEP-NETs (GEP-NOC)

Gastroenteropancreatic Neuroendocrine Tumors

France
Ipsen

Completed

Community-based Neuroendocrine Tumor (NET) Research Study

Gastroenteropancreatic Neuroendocrine Tumors

United States
Advanced Accelerator Applications

Completed

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Gastroenteropancreatic Neuroendocrine Tumors

United Kingdom, Italy, Netherlands, Poland
Duke University
Merck Sharp & Dohme LLC; Ipsen

Completed

Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET)

Gastroenteropancreatic Neuroendocrine Tumors

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Well-differentiated Non-functional NET of Thoracic Origin | Well-differentiated Non-functional NET of Gastrointestinal Origin | Well-differentiated Non-functional NET of Pancreatic Origin | Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

United States, Italy, Spain, Japan, Belgium, Netherlands, Germany, France, Canada, Austria, United Kingdom, Australia
AbbVie

Terminated

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Glioblastoma | Medullary Thyroid Cancer | Malignant Melanoma | Other Solid Tumors | Large-Cell Neuroendocrine Carcinoma | Neuroendocrine Prostate Cancer | High Grade Gastroenteropancreatic Neuroendocrine Carcinoma | Other Neuroendocrine Carcinoma

United States
PharmaMar

Recruiting

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Glioblastoma | Pancreatic Adenocarcinoma | Neuroendocrine Tumors | Advanced Solid Tumors | Mesothelioma | SCLC | Gastric Carcinoma | Endometrial Carcinoma | Colorectal Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Epithelial Ovarian Carcinoma | Soft Tissue Sarcoma (Excluding GIST)

United States, Spain, France, Germany, Italy, Switzerland
Phanes Therapeutics

Recruiting

A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Small Cell Lung Cancer (SCLC) | Large Cell Neuroendocrine Cancer (LCNEC) | Neuroendocrine Prostate Cancer (NEPC) | Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

United States
Translational Research in Oncology
Bayer; Novartis

Withdrawn

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers (REFIT-MSS)

Soft Tissue Sarcoma | Small Cell Lung Carcinoma | Colorectal Neoplasms | Anal Squamous Cell Carcinoma | Malignant Pleural Mesothelioma | Castrate Resistant Prostate Cancer | Gastroenteropancreatic Neuroendocrine Neoplasm | Neuroendocrine Carcinoma of Prostate

Clinical Trials on Gastroenteropancreatic

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations